- Home
- SLGL vs GALT Comparison
SLGL vs GALT Comparison
Compare SLGL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGL | GALT |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 199.2M |
| IPO Year | 2016 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SLGL | GALT |
|---|---|---|
| Price | $69.80 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $110.00 | $8.50 |
| AVG Volume (30 Days) | 17.5K | ★ 327.1K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $1.15 |
| 52 Week High | $97.97 | $7.13 |
Technical Indicators
Market Signals| Indicator | SLGL | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 37.48 |
| Support Level | $66.47 | $2.07 |
| Resistance Level | $71.43 | $3.32 |
| Average True Range (ATR) | 10.59 | 0.20 |
| MACD | -1.55 | -0.03 |
| Stochastic Oscillator | 19.72 | 3.85 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.